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ing author. Tel.: +46 186
ess: christer.janson@meSummary The objective of the present study was to examine differences in the
characteristics and management of hospitalised patients with chronic obstructive
pulmonary disease (COPD) and to determine factors related to the duration of the
hospital stay in the Nordic countries.
The study comprised 416 patients from five University Hospitals (Bergen,
Reykjavik, Uppsala, Tampere and Copenhagen). The patients were interviewed
and spirometry was performed. Psychological status was assessed with the Hospital
Anxiety and Depression questionnaire and quality of life with the St. Georges’
Hospital Respiratory Questionnaire.
The mean age was 69 years, 51% were women. The majority of the patients (76%)
had severe COPD (GOLD stage III and IV) and 24% were on long-term oxygen therapy.
Forty five % of the patients had cardio-vascular disease and 11% diabetes. In Bergen,
Uppsala and Tampere over half of the patients had anxiety and depression but the
prevalence of psychiatric co-morbidity was lower in Reykjavik and Copenhagen. The
median length of the hospitalisation was 7–8 days in four of the five centres but two
times higher in Reykjavik. The independent predictors for a longer hospitalisation
was living alone (+3 days), being on long-term oxygen (+8 days) and having diabetes
(+5 days).
In conclusion, this study revealed substantial differences in the characteristics
and management of hospitalised COPD patients between departments of respiratoryElsevier Ltd. All rights reserved.
114115; fax: +46 186110228.
dsci.uu.se (C. Janson).
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Characteristics of hospitalised patients with COPD in the Nordic countries S11disease in five Nordic university hospitals. Living alone, concurrent diseases like
diabetes and long-term oxygen therapy are predictors of more prolonged
hospitalisation periods.
& 2006 Elsevier Ltd. All rights reserved.IntroductionAcute exacerbations of chronic obstructive pul-
monary disease (COPD) is becoming one of the most
common causes for hospitalisations in the Nordic
countries.1 As an effect the cost for the manage-
ment of COPD is increasing and the total cost for
COPD in Sweden 1999 was estimated to 982 million
Euro.2 Exacerbations account for 35–45% of the
total per capita health-care costs for COPD and the
cost for an COPD exacerbations that requires a visit
to an emergency care unit or a night in hospital was
in 1999 estimated to be on average 2400 Euro per
patient in Sweden.3
During the last decades international guidelines
on the management of COPD have been developed4
and these guidelines have been implemented
in all the Nordic countries. Despite the socio-
economic similarities and the common guide lines
data from official statistics have shown consider-
able differences in hospitalisation rates for COPD
and asthma between the Nordic countries with a
variation from 533 discharged patients per 100,000
inhabitants in Denmark to 147/100,000 inhabitants
in Finland.5 This may to some extent be explained
by differences in the prevalence of smoking and
COPD in the Nordic countries,5–8 but may also
reflect national differences in the management
of COPD.
In a retrospective study covering 500 patients
with obstructive lung disease from five university
teaching hospitals in the Nordic countries we found
that there were large differences in the diagnostic
procedures and the length of hospitalisations
between the hospitals.9 The retrospective study
also underlined that there is a high readmission
rate in hospitalised patients with obstructive lung
disease with 50% of the patients having been
readmitted within 12 months after being discharge
from hospital.6 In year 2000–2002, a prospective
Nordic multicenter study was performed.10 The aim
of this investigation was to study the management
and prognosis in hospitalised patients with COPD in
the Nordic countries.
The aim of this investigation was to compare the
characteristics and management of hospitalised
COPD patients from one departments of respiratory
medicine in each of the five Nordic countries.A secondary aim was to analyse risk factors of
prolonged hospitalisations.Method
The study aimed to include 100 patients each from
five University Hospitals (Bergen, Reykjavik, Up-
psala, Tampere and Copenhagen) in the Nordic
countries (Fig. 1). The departments included were:
The Department of Respiratory Medicine and
Allergology, Akademiska sjukhuset, Uppsala, Swe-
den; The Department of Thoracic Medicine, Hauke-
land University Hospital, Bergen, Norway; The
Department of Respiratory Medicine, Tampere
University Hospital,Tampere, Finland; The Depart-
ment of Respiratory Medicine, Vifilstadir University
Hospital, Gardabaer, Iceland and The Department
of Respiratory Medicine, Hvidovre Hospital, Copen-
hagen Denmark.
Consecutive patients from each of the partici-
pating hospitals were included provided that they
had been admitted with acute exacerbations of
obstructive lung disease (asthma, chronic bronchi-
tis, chronic obstructive bronchitis or emphysema)
during the year 2000–2001. As the majority of the
patients had COPD all patients with asthma
(n ¼ 66) were excluded and reported are only data
from the 416 patients that fulfilled the criteria for
COPD according to the Global Initiative for Chronic
Obstructive Pulmonary Disease stage 1 or higher.4
The following data were collected at discharge
from the respective pulmonary departments:1. Questionnaire that included information on the
following: age, gender, length of hospital stay,
smoking history, education, and family situation
(living at home, assisted at home, nursing home,
with spouse, alone or with others).2. Spirometry, body weight and height. Predicted
values for forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) were calculated
based on the European Coal and Steel Union
reference values.113. Health Related Quality of Life was assessed using
the disease-specific St. George’s Respiratory
Questionnaire (SGRQ). It has three components:
symptoms, activity and impact, in addition to
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Figure 1 Location of the study centres.
C. Janson et al.S12total score.12 Higher scores indicate worse
health status.4. Anxiety and depression were evaluated with the
Hospital Anxiety and Depression Scale (HADS).13
It is composed of two parts, one with 7 questions
that are related to anxiety and another with 7
questions that are related to depression. A score
of 8 or greater on either part was used as the
cut-off point for diagnosing anxiety and depres-
sion, respectively.5. From the patient records information was
collected on treatment at discharge, including
long-term oxygen therapy and medications.
Assessment of co-morbidity was based on the
diagnosis used by the treating physician. Dia-
betes mellitus was considered to be present if
the patient was using medications for diabetes.
Hypertension, ischaemic heart disease or atrial
fibrillation were considered to be present when
diagnosed by the attending physician and the
patient was using appropriate medications.Statistics
Statistical analyses were performed using StatView
5.0 (SAS Institute Inc, Cary, NC, USA). Chi-squared
test and one-way analysis of variation were usedwhen analysing differences between the hospitals.
Multiple linear regression was used to analyse
determinants for the length of hospitalisation. In
this analysis the duration of hospitalisation was log
transformed. A P-valueo0.05 was considered sta-
tistically significant.Results
The analysis included 205 men and 211 women,
mean (7SD) age 69710 years. The characteristics
of the 416 patients in the different hospitals are
displayed in Table 1. Many of the patients were
living alone (52.1%) and cardio-vascular co-morbid-
ity (45.0%) and diabetes (10.6%) was common.
Significant differences in the characteristics of the
patients between the hospitals were found for all
variables except age, lung function and the
prevalence of diabetes (Table 1).
A large majority of the patients (76.0%) had
severe COPD (GOLD stage III and IV) with no
significant difference between the centres
(Fig. 2). In Bergen, Uppsala and Tampere over half
of the patients had anxiety and depression but the
prevalence of psychiatric co-morbidity was lower in
Reykjavik and Copenhagen (Fig. 3). Many of the
patients had low health-related quality of life, but
ARTICLE IN PRESS
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
I II III IV P=0.29
Bergen Uppsala Reykjavik Tampere Copenhagen
Figure 2 Severity classification according to the GOLD criteria in hospitalised COPD patients.
Table 1 Characteristics of the patients (mean+SD or %).
Bergen
(n ¼ 100)
Uppsala
(n ¼ 87)
Reykjavik
(n ¼ 81)
Tampere
(n ¼ 60)
Copenhagen
(n ¼ 88)
P-value
Age 70711 69711 6979 67711 70710 0.22
Women 46 60 54 32 57 0.007
Smokers 27 33 13 27 28 0.04
Pack years 25717 35725 44723 34726 40721 o0.0001
Living alone 39 53 59 40 68 0.0003
FEV1 (% of predicted) 40717 36718 43721 39718 35717 0.07
Cardio-vascular
disease
40 67 42 50 28 o0.0001
Diabetes 15 9 16 5 6 0.06
Characteristics of hospitalised patients with COPD in the Nordic countries S13patients in Uppsala and Reykjavik had higher
quality of life than patients from the three other
hospitals (Fig. 4).
A majority of the patients were on maintenance
treatment with inhaled corticosteroids but there
where considerable difference in the use of other
pharmacological agents (Table 2). Patients in
Reykjavik were using ipratropium and nebulised
treatment considerably less often than patients
from the other hospitals. The number of patients on
long-term oxygen was 98 (23.6%).
The median length of the hospitalisation was 7–8
days in four of the five centres. The only exception
was Reykjavik were the median length of hospita-
lisation was two times higher than in the otherhospitals (Fig. 5). The independent predictors for a
longer hospitalisation was living alone, being on
long-term oxygen and having diabetes, while
patients that were current smokers had a signifi-
cantly shorter length of hospitalisation (Table 3).Discussion
The main result of this investigation is that there
were quite large differences in the characteristics
and treatment of COPD patients between these five
Nordic university hospitals. There was a wide
variation in the length of hospital stay. Patients
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Figure 3 Anxiety and depression in patients hospitalised because of COPD.
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Figure 4 Health-related quality of life measured as total score using the St. George Respiratory Questionnaire (Box
plot, showing the median, the 10th, 25th, 75th and 90th percentile).
C. Janson et al.S14who are old, have concurrent diseases like diabetes
and patients on long-term oxygen therapy had
prolonged hospitalisation periods.
Like in our previous retrospective study9 the length
of hospital stay was longest in Reykjavik. This is also inaccordance with official statistics were the mean
hospital stay for patients with obstructive lung
diseases in year 2002 was 8 days in Iceland compared
to 5–6 days in the other Nordic countries.5 The
difference might have to do with the facts that a
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Table 2 Maintenance treatment at discharge (%).
Bergen
(n ¼ 100)
Uppsala
(n ¼ 87)
Reykjavik
(n ¼ 81)
Tampere
(n ¼ 60)
Copenhagen
(n ¼ 88)
P-value
Ipratropium MDI 32 68 0 47 30 o0.0001
Nebulised therapy 64 19 8 25 41 o0.0001
Long acting beta-2
agonists
73 49 69 73 41 o0.0001
Inhaled
corticosteroids
62 81 69 85 56 0.0002
Theophylline 43 32 12 38 10 o0.0001
Long term oxygen
therapy
29 20 35 18 15 0.01
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Figure 5 Length of hospitalisation in the five Nordic hospitals (Box plot, showing the median, the 10th, 25th, 75th and
90th percentile).
Table 3 Factors associated with the length of hospitalisation.
Adjusted estimate 95% confidence interval Effect calculated
as days
Current smokers 0.11 0.19, 0.02 3
Living alone 0.09 0.02, 0.16 +3
Long term oxygen therapy 0.16 0.07, 0.25 +8
Diabetes 0.16 0.04, 0.27 +5
Adjusted for hospital, age, gender, smoking, educational level, FEV1, health-related quality of life and psychological status.
Characteristics of hospitalised patients with COPD in the Nordic countries S15large proportion of the patients were living alone in
combination with a shortage of long-term care in
Reykjavik. It should also be noted that the number of
patients was limited and only one department in each
country was selected. The results can therefore not be
generalised to represent national differences on how
COPD is managed in the different Nordic countries.
Cardio-vascular co-morbidity was as expected
common and results from other studies show thatCOPD patients with this kind of co-morbidity are
more prone to have severe exacerbations than
patients with only COPD.14 Diabetes was also
relatively common which is to be expected in this
elderly population although there are indications
that patients with COPD may have a higher
prevalence of type II diabetes than expected from
age alone.15 In our study patients with diabetes had
longer hospitalisation periods probably due to the
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systemic corticosteroid treatment.
In three of the centre over half of the patients
had probable anxiety and depression which is much
higher than found in a study of a Swedish general
population.16 The high prevalence of psychiatric
co-morbidity may be important as anxiety and
depression has been found to be associated to an
increased risk of readmissions in emergency-trea-
ted patients with asthma and COPD.17
While it was expected that patients living alone
and patients on long-term oxygen therapy would
have increased hospital stays the finding of sig-
nificantly shorter hospitalisations in COPD patients
that still are smokers is surprising. One possible
explanation could be that smoking is prohibited in
most hospitals in the Nordic countries and patients
that are addicted may therefore be more moti-
vated to leave the hospitals earlier. Nevertheless
efforts to motivate hospitalised smoking COPD
patients to quite smoking should be encouraged
as the risk of new hospital admissions was reduced
by about 40% in COPD patients that managed to
quite smoking in a Danish study.18
The data on maintenance treatment showed both
differences and similarity between the hospitals.
Like in our previous study very few of the Icelandic
patients were using ipratropium, while the use of
inhaled corticosteroids and long acting beta2-
agonist was relatively widespread in all the
hospitals. The majority of the patients had severe
COPD and the use of inhaled corticosteroids is
therefore in accordance with the guidelines,4 as
this treatment has been showed to reduce the risk
of rehospitalisations although the effect is not very
large.19
In conclusion there was a wide variation in the
characteristics, treatment and length of hospital
stay between the hospitals. Patients that live
alone, have concurrent diseases like diabetes and
patients on long-term oxygen therapy often have
more prolonged hospitalisation periods. The pa-
tients have now been followed for 12 months and
analyses of this data will give an assessment of the
different risk factors for readmission of COPD in the
Nordic countries. This information may also give
indications on how to lower the health economic
burden of COPD in Northern Europe.
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